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Summary.-The tumour specific antigens and tumour associated embryonic anti-
gens expressed on chemically induced rat hepatomata and sarcomata have been
shown to be different by means of blocking antibody studies. Serum from multi-
parous female rats contained blocking antibody which protected both tumour and
embryo cells from the in vitro cytotoxic effect of lymph node cells from multiparous
donors. These sera did not, however, block the cytotoxicity of lymph node cells
from tumour immune rats for cells of the immunizing tumour. In addition, the
tumour specific rejection antigens and embryonic antigens have been shown to
have dissimilar locations in tumour cells.
AMINOAZO dye induced rat hepatomata
and 3-methylcholanthrene induced rat
sarcomata express tumour specific rejec-
tion antigens, defined by their capacity
to elicit immunitytotransplantedtumours
in syngeneic recipients (Baldwin and
Barker, 1967a; Baldwin et al., 1971a).
These neoantigens are characterized by a
high degree of specificity so that cross-
reaction between tumours is uncommon
(Baldwin, 1973). These tumours also
express neoantigens at the cell surface
which are normally present only on
embryo cells during foetal development
and are immunogenic in the adult host
(Baldwin, Glaves and Pimm, 1971b;
Baldwin, Glaves and Vose, 1972b, c;
Baldwin et al., 1972a). This raises the
possibility that the so-called " tumour
specific rejection antigens " are, in fact,
re-expressed embryonic antigens. This
hypothesis has been advanced in studies
with hamster cells transformed with
SV40 and adenovirus 31 where immuniza-
tion with irradiated embryo cells can
produce immunity against transplanted
tumour cells (Coggin, Ambrose and Ander-
son, 1970; Coggin et al., 1971). Since the
embryonic antigens detected on chemically
induced rat tumours are cross-reacting
(Baldwin et al., 1972b) and the tumour
rejection antigens are specific for each
individual tumour, it seems unlikely that
this is the case. The objective of this
study has been to differentiate further
between the tumour specific and embry-
onic antigens associated with chemically
induced rat tumours.
Previous studies have indicated that
lymph node cells (LNC) from multiparous
female rats are cytotoxic for cultured
tumour cells (Baldwin et al., 1972a, b).
Similarly, LNC from rats immunized
against a particular tumour are cytotoxic
for cells of the immunizing tumour
(Baldwin and Embleton, 1971; Baldwin,
Embleton and Robins, 1973b). Serum
from tumour immune donors also contains
antibody which protects cells of the
immunizing tumour from in vitro attack
by LNC from tumour-immune rats (Bald-
win et al., 1973b). In this present study
the ability of serum from multiparous
female rats to block the cytotoxicity of
multiparous and tumour immune donor
LNC for tumour and embryo cells was
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determined, to differentiate between em-
bryonic and tumour specific antigens.
Preliminary evidence indicated that
the embryonic antigen was present in the
soluble cytoplasmic protein (cell sap)
fraction of tumour homogenates (Baldwin
et al., 1972c) as well as being expressed
at the cell surface. In order to charac-
terize further these embryonic antigens,
their localization in tumour cells has
been identified using cell fractionation
studies similar to those of Baldwin and
Moore (1969) which established that the
tumour specific rejection antigens of
aminoazo dye induced hepatomata are
intimately associated with the plasma
membrane and are not present in soluble
cytoplasmic fractions.
MATERIALS AND METHODS
Rats and tumours.-Rats of a Wistar
strain maintained in this department since
1952 by continuous single line brother-sister
matings were used. Their genetic identity
was confirmed by routine exchange of skin
grafts. Hepatomata were induced by oral
administration of 4-dimethylaminoazoben-
zene in a low protein diet. Sarcomata were
induced by the subcutaneous injection of
3-methylcholanthrene. Tumours were pas-
saged subcutaneously in syngeneic rats of
the same sex as the original host.
Serum and lymph node cell donors.-
Tumour immune lymph node cells were
taken from rats immunized by the implanta-
tion of multiple, heavily irradiated (15,000
rad) tumour grafts or by excision of pro-
gressively growing tumour grafts. Immun-
ized rats rejected repeated challenge inocula
of viable tumour cells which grew con-
sistently in untreated controls. Serum and
lymph node cells were also taken from rats
having had at least 4 pregnancies and which
were pregnant at the time of assay. Age
matched virgin female rats were used as
controls.
Cell cultures.-Monolayer cell lines were
initiated from single cell suspensions of
trypsinized tumour tissue. Cell cultures
were maintained by serial subculture in
Eagle's MEM supplemented with 10% calf
serum and antibiotics. Embryo cell cultures
were prepared by mechanical dissociation
of whole, 15-day old embryos (aged by size
and development (Witschi, 1956)) dissected
free of extra-embryonic membranes and
maintained in Waymouth's medium supple-
mented with 20% foetal calf serum and
antibiotics. These embryo cultures were
used as a source of target cells for cyto-
toxicity assays between the first and sixth
passage.
Blocking tests.-Blocking tests were con-
ducted using both Falcon Microtest (No.
3034) and Microtest II (No. 3040) plates.
Both systems produced similar results and
these are presented without distinction.
Microtest.-Tumour or embryo cells from
monolayer cultures were plated in the wells
of Falcon Microtest plates (500-750 cells/
well) in 10 ,ul volumes, dispensed using a
repeating dispenser attachment on a 500 I
Hamilton syringe. After 24 hours, incuba-
tion at 37°C in a humidified atmosphere of
95% air/5% CO2 to allow cell adhesion,
medium was replaced by 10 ,ul aliquots of
control or test serum diluted 1: 4 in MEM
buffered at pH 7.3 with HEPES (40 mmol/l
N-2-hydroxyethylpiperazine-N'-ethanesulph-
onic acid, Sigma Chemical Co.). All sera
were heat inactivated at 56°C for 30 min
before use. Following incubation for 60 min
at 37°C, the diluted serum was removed and
replaced by LNC suspensions (target: effec-
tor cell ratio 1: 75) in MEM (HEPES-
buffered) supplemented with 10% calf serum.
The plates were incubated for a further 2
days before being washed, fixed and adherent
cells counted.
Microtest II.-Tumour cells were plated
in the wells of Falcon Microtest II plates
(100 cells/well). After 24 hours incubation,
medium was replaced by 0 05 ml aliquots of
heat inactivated test or control serum
diluted 1: 4 in MEM (HEPES-buffered).
Following incubation for 45 min at 37°C
the diluted serum was removed and replaced
by LNC suspensions (5 x 105 cells in 0-2 ml
HEPES-bufferedMEMperwell). Theplates
were incubated for a further 45 min and
0.05 ml aliquots of 50% calf serum in
HEPES-buffered MEM were added to each
well. After 2 days incubation the cells were
washed, fixed and stained, and adherent
cells counted (Baldwin et al., 1973b).
Cell fractionation.-Tumour, embryo and
normal liver tissue were finely minced and
homogenized in 0-25 mol/l sucrose containing
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2 mmol/l CaCl2, 2 mmol/l Mg C12 and 1 mmol/l
NaHCO3 (pH 7.6) using an Ultraturrax
tissue homogenizer operated at approxi-
mately -1 maximum output. Remaining
connective tissue debris was removed by
filtration through 60-mesh stainless steel
screens and homogenization continued at
5-min intervals with cooling until approxi-
mately 90% cellular disruption was achieved.
Homogenates were centrifuged at 1000 g
for 30 min to remove cells and nuclei and
the 1000 g supernatants further centrifuged
at 78,000 g for 30 min. The sediment was
taken as an extranuclear membrane fraction
(ENM) and the supernatant as the soluble
cytoplasmic protein (cell sap) fraction. All
samples were dialysed against phosphate
buffered saline (pH 7-3) before storage at
-200C.
Membrane immunofluorescence tests.-The
indirect membrane immunofluorescence test
was performed on viable tumour and embryo
cells in suspension as previously described
(Baldwin and Barker, 1967b; Baldwin et al.,
1972b). Fluorescence indices were calculated
from the proportions of unstained cells
exposed to test serum compared with
control sera and a value of 0-30 or greater
was taken to represent a significant reaction.
Antigen assay.-Subcellular fractions were
assayed for embryonic antigen activity by
their capacity to absorb antibody from
multiparous rat sera reacting with hepatoma
D23 cells, as detected by the membrane
immunofluorescence test (Baldwin andMoore,
1969; Baldwin and Glaves, 1972). Antigenic
activity was indicated by a reduction of the
fluorescent index to below the value taken
to reflect a significant reaction (0-30) with
absorbed serum, as compared with multi-
parous rat serum diluted with equivalent
volumes of phosphate buffered saline.
Immunization of rats with ENM and cell
sap fractions.-Syngeneic rats were immun-
ized with tumour or embryo ENM fractions
suspended in medium 199, pH 7-6, or con-
centrated soluble fractions, by repeated
subcutaneous injections at 7-14 dayintervals.
Rats received 4 such injections so that each
received 30-50 mg protein ENM or 30-120
mg soluble cell sap protein. Animals were
bled by cardiac puncture under ether
anaesthesia, the serum collected and stored
at -20°C before testing for reactivity
against embryo cells by membrane immuno-
fluorescence tests.
Protein analysis.-Protein was determined
by the method of Lowry et al. (1951).
RESULTS
Blocking of multiparous donor lymph node
cell cytotoxicity by multiparous sera
Lymph node cells from multiparous
rats were cytotoxic for hepatoma D23
cells and, as shown in Table I, this
cytotoxicity was abrogated by pre-expo-
sure of plated tumour cells to heat
inactivated sera from multiparous donors.
Six of 11 sera were effective in signifi-
cantly reducing LNC cytotoxicity pro-
ducing abrogations of 49.8% to 77.8%.
TABLE I.-Blocking of Multiparous Rat Lymph Node Cell Cytotoxicity for
Hepatoma D23 Target Cells by Multiparous Rat Sera (MPS)
No. of cells* remaining
after treatment with
Blocking sera
4550 Control
4644 MPS
4552 MPS
4589 MPS
4685 MPS
4785 Control
4786 MPS
4787 MPS
4766 MPS
4770 MPS
4586 MPS
4585 MPS
4571 MPS
* Mean ± s.e.
Control LNC
84-6±4-6
103-8±5-9
107-0±6-6
91-6±11-2
102- 1±10-6
78-6410-3
109-7±9-5
5022±3. 1
58-3±4-7
46-9±6-5
72-0±10-4
68-8±6-2
78-5±4-3
M.P. LNC
50-9±2-7
89-0±4-8
95- 6±6-2
83-5±4-9
85-0±6-3
44-0±5-5
51- 3±4-2
34-3±3-9
45-4±3-9
23-8±3- 1
64-2±5-2
58-2±5-8
43-4±5-3
Percentage
cell
reduction
39.9
14-0
10-6
8-9
16-8
44-0
53-2
31-7
22-1
50-7
10-8
15-4
44-7
Percentage
abrogation
64-7
73-3
77-8
58-0
0-0
28-0
49-8
0-0
75-5
65-0
0-0
P <
0-025
0 025
0 025
0-10
0-10
0 05
0- 05
0-05
0-495
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TABLE II.-Blocking of Multiparous Rat Lymph Node Cell Cytotoxicityfor
Sarcoma Mc7 Target Cells by Multiparous Rat Sera (MPS)
Blocking sera
Control
4551 MPS
4644 MPS
4552 MPS
4589 MPS
4585 MPS
Control
4786 MPS
4787 MPS
4586 MPS
4766 MPS
4585 MPS
4770 MPS
4571 MPS
5581 MPS
No. of cells* remaining
after treatment with
Control LNC M.P. LNC
92 1±4*6 63 9±441
75-2±6 8 56 1±2*9
82 6±7 7 541±1-8
76-7±2*8 62-9±4 0
65 0±5 9 45 8±3 4
72 8±4-7 81 2±6 5
57 6±3-0 27*5±2*5
56 3±4 5 26 9±1-1
63 0±4-1 36 4±3 9
52-9±5-9 39 9±1 9
56 8±3 6 321±2-1
36-7±1 8 33 4±2 7
61 5±4*9 30 3±3 7
45-3±3 8 33 7±2-0
59-6±2 9 27 0±2 2
Percentage
cell
reduction
30 7
25.4
35.3
18 1
29 6
0o
52*3
52-3
42 2
24*6
43.5
8 9
41*2
25-6
54.7
Percentage
abrogation
17 1
0o0
411
3.4
100.0
0.1
19 2
52 9
16 8
82 8
21 2
51-0
0o0
P <
0 20
0 05
0 20
0 0005
0 45
0 30
0-0125
0 20
0 0005
0-15
0 0025
* Mean ± s.e.
TABLE III.-Blocking of Multiparous Rat Lymph Node Cell Cytotoxicityfor
Cultured 15-day Old Embryo Cells by Sera from Multiparous Rats (MPS)
No. of cells* remaining
after treatment with Percentage
r
A 5 cell Percentage
Blocking sera Control LNC M.P. LNC reduction abrogation P <
4999 control 158 1±6 2 126 6±5 1 19 9
4970 MPS 118 445 7 136 2±4 8 0.0 100 0 0.0005
4890 MPS 137 6±6 5 138 8±6 3 -1.0 104 9 0 025
4815MPS 112-5±6-0 104-9+6-9 6*8 66-1 0.10
4975MPS 170 7+7 8 182 8±9 7 0.0 100*0 0*005
4947 MPS 149 2±4 8 141 2±12 2 5.3 73 1 0.05
* Mean ± s.e.
TABLE IV.-Blocking of the Cytotoxicity of Hepatoma D23 Immune Lymph
Node Cellsfor D23 Target Cells by Multiparous Rat Sera (MPS)
No. of cells* remaining
after treatment with Percentage
A 5 cell Percentage
Blocking sera Control LNC Immune LNC reduction abrogation P <
Control 105-5±10-3 76-1±7-9 27-8
4589MPS 114-9±14-4 64 8±5-8 43-6 0.0
4754MPS 131-9±9 6 91-0±6 2 31-0 0.0 -
4705 MPS 95- 8±4- 2 82- 5±6-1 13- 8 50 3 0-15
4644MPS 112-0±8-9 77-1±5-6 31-1 0.0
4685MPS 116-4+9-3 86-3±9 4 25-9 7 0 0 49
Control 146-9±11 0 115-4±5-7 21-3
5185MPS 108-2±6-3 93-9±5-7 13-3 37-8 0-15
5039MPS 122-3-f5-9 96-4±4-8 21-2 0-5 0-495
5001MPS 115-8±6-1 96-5±5-1 16-9 20-6 0-20
4075MPS 114-2±7-1 104-2±5-9 8-8 58-2 0*10
4937MPS 117-7±4-7 85-0+5-0 27-8 0.0
* Mean ± s.e.
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TABLE V.-Blocking of the Cytotoxicity ofSarcoma Mc7 Immune Lymph Node
Cellsfor Mc7 Target Cells by Multiparous Rat Sera (MPS)
Blocking sera
Control
5185 MPS
7574 MPS
5119 MPS
4564 MPS
Control
4564 MPS
4620 MPS
4705 MPS
4619 MPS
No. of cells* remaining
after treatment with
Control LNC Immune LNC
112-2±7-2 80-2+5-9
90-5±6-4 68-4±4-0
155-7±12-6 113-4+10-0
145-6±9-2 88-244-9
120-5±9-5 84-0±9-0
57*542-0 44-1 2-6
62-0±4-1 45-6±3-3
78-8±2-6 56-7±3-6
65-8±5-2 53-1±4-5
64-9±4-2 47-8±4-7
* Mean i s.e.
TABLE VI.-Blocking of Tumour Immune Lymph Node Cell Cytotoxicityfor
Cultured 15-day Old Embryo Cells by Multiparous Rat Sera (MPS)
No. of cells* remaining
after treatment with
Blocking sera Control LNC
Hepatoma D30 immune LNCs
Control 68-8±5-3
4929 MPS 61 2±5 1
4975 MPS 64-2±2- 8
4987 MPS 64-5±2- 6
4988 MPS 58-3±2-1
5001 MPS 57 7±5 9
Hepatoma D23 immune LNCs
Control
4813 MPS
4815 MPS
4929 MPS
4871 MPS
4873 MPS
4929 MPS
5001 MPS
114 3±5 0
74 9±6 0
104-5±7-4
87-4±5-9
100-0±9-3
108-4±11-8
90-316-3
82 -6±8-5
Immune LNC
528±5-6
46-5±4-0
67-3±5-2
58-3±3*5
61-7±3-3
60- 1±2 - 3
90*5±4-6
83 - 1±8 - 6
86-3±7-3
108-5±7-5
83 0±8-3
89- 8±4- 4
74 3±7 0
87- 648- 7
* Mean ± s.e.
In comparable tests with sarcoma Mc7
(Table II), pretreatment of plated target
cells with .5 of 13 multiparous sera
produced significant abrogation of multi-
parous LNC cytotoxicity (41.1% to 100%)
compared with the effect of normal
virgin control sera. In addition, LNC
from multiparous rats were cytotoxic' for
cultured 15-day old embryo cells and
this cytotoxicity was blocked by pre-
treatment of the target cells with multi-
parous rat serum (Table III). Thus, 4
of 5 sera significantly reduced the cyto-
toxic index of multiparous LNC for
embryo cell targets by 73.1% to 100%.
Blocking of tumour immune lymph node
cell cytotoxicity by multiparous sera
Table IV shows the results of tests
in which hepatoma D23 target cells were
incubated with sera from multiparous
rats before treatment with LNC from
rats specifically sensitized to this hepa-
toma. None of the 10 sera significantly
reduced the specific cytotoxicity of these
LNC for cells of the immunizing tumour.
Similar results were obtained in studies
using sarcoma Mc7 as target cells (Table
V). Thus, none of the 8 multiparous sera
significantly reduced the cytotoxicity of
Mc7 immune LNC for Mc7 target cells,
Percentage
cell
reduction
28-5
24-4
26-8
39-5
30 3
23-0
26-4
27-9
19-4
26-4
Percentage
abrogation
14-6
5.9
0.0
0.0
0.0
0*0
16-8
0.0
P <
0-20
0 40
0 475
Percentage
abrogation
Percentage
cell
reduction
23-3
24-0
0.0
9-6
0.0
0.0
20-8
0
17-4
0
17-4
17-2
17-7
0
0.0
100.0
60-0
100.0
100*0
100-0
16-4
100-0
16-4
17-6
14-9
100-0
0 025
0-15
0-025
0*05
0-01
0 30
0-001
0 35
0 30
0 35
0-025
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compared with the cytotoxic index of
these LNC in the presence of virgin
control sera.
LNC from tumour immunized rats
are cytotoxic for cultured 15-day old
rat embryo cells (Baldwin, Glaves and
Vose, 1974). This cytotoxicity could be
abrogated by incubating the embryo
target cells with serum from multiparous
rats before treatment with LNC from
tumour immune rats (Table VI). Three
of 5 multiparous rat sera significantly
reduced the cytotoxicity of hepatoma
D30 immune LNC for 15-day old embryo
cells by 60% to 100%. Similarly, 3 of
7 sera from multiparous rats reduced the
cytotoxicity of hepatoma D23 immune
LNC for embryo cells.
Subcellular localization of embryonic anti-
gen
Rat antisera to both tumour and
embryo cell sap and extranuclear mem-
brane fractions reacted in immunofluo-
rescence tests with 15- and 16-day old
rat embryo cells (Table VII). Whilst
antisera to membrane fractions also re-
acted with tumour cells, antisera to cell
sap fractions did not. The reactivity
of anti-tumour cell sap antisera with
embryo cells is taken to indicate that the
TABLE VII.-Immunofiuorescence Tests with Serafrom Rats Immunized with
Tumour and Embryo Subcellular Fractions
Fluorescence indices following reaction with
S3erum donor immunized
with
Cell sap
Sarcoma Mc7
Sarcoma MclO
Sarcoma Mc16
Hepatoma D23
14-day embryo
Extranuclear membrane
Sarcoma Mc7
Sarcoma MclO
Sarcoma Mc16
Hepatoma D23
Hepatoma D30
Hepatoma D31
14-day embryo
Embryo cells (15-16 days) Immunizing tumour
0-45, 0-69, 0-42
0-36, 0-32, 0-57
0-51, 0-43, 0-75
0- 33, 0-66, 0-51
0-43, 0-51, 0-71
0-68, 0-63, 0-47
0-38, 0-43, 0-56
0- 39
0-93, 0-33, 0-31
0-37, 0-61
0-38, 0-48
0-31, 0-38
0-00, 0-00, 0-08
0-08, 0-04, 0-03
0-02, 0-04, 0-00
0- 14, 0-00, 0-08
0-32, 0-40,
0-59, 0-45,
not tested
0-38, 0-61,
0-49, 0-50,
0-31, 0-42,
0-46
0-51
0-54
0-37
0-47
TABLE VIII.-Neutralization of the Reaction of Multiparous Rat Sera with
Hepatoma D23 Cells by Absorption with Cell Sap Fractions
F.I. against hepatoma
D23 cells
Absorption conditions*
Cell sap fraction of: mg protein/ml serum
Hepatoma D23 50- 0
14-day embryo 20-0
19-day embryo 25-0
Normal liver 79- 0
Hepatoma D23
14-day embryo
20-day embryo
Normal liver
Hepatoma D23
14-day embryo
50-0
20-0
18-0
79-0
50-0
20-0
Unabsorbed Absorbed
serum serum
0-86 0-09
0-86 0-18
0-86 0-46
0-86 0-75
0-56
0-56
0-56
0-56
0-15
0-28
0- 43
0- 50
0- 37, 0-35 0- 18, 0- 08
0-37, 0-35 0-12, 0-12
* Absorbed for 2 hours at 4°C.
Multiparous
rat serum
5118
5119
4179
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cell sap as well as the plasma membrane
contains embryonic antigen.
Embryonic antigen can be detected
at the plasma membrane of tumour
cells by membrane immunofluorescence
staining with multiparous rat serum
(Baldwin et al., 1972a, b). As shown in
Table VIII, this reaction with hepatoma
D23 cells could be abolished or signifi-
cantly reduced by absorption of the
serum with either hepatoma D23 or
14-day old embryo cell sap (20-50 mg
cell sap protein/ml antiserum). Absorp-
tion with cell sap fractions from 19- and
20-day old embryos (25 and ] 8 mg
protein/ml antiserum respectively) did
not reduce significantly the F.I. of multi-
parous rat serum with hepatoma D23.
Absorption of MPS with cell sap fractions
of adult liver (up to 79 mg protein/ml
antiserum) were also ineffective in reduc-
ing fluorescent membrane staining.
DISCUSSION
During pregnancy, multiparous female
rats are exposed to antigens expressed
on the cells of the foetus which may
elicit the formation of sensitized lymphoid
cells. Iftumour cells express both embry-
onic and tumour specific antigens, tumour
immunization may result in the develop-
ment ofseparate lymphoid cell populations
directed against both ofthese specificities.
Differential blocking of tumour or embryo
cells with multiparous rat serum from
attack by these lymph node cell popula-
tions provides an approach for distin-
guishing between tumour specific and
embryonic antigens.
Sera from multiparous rats known to
contain antibody directed against tumour
associated embryonic antigens (Baldwin
et al., 1971b; 1972a, b) can block cell
surface embryonic antigens on both em-
bryo and tumour target cells. Plated
cells are not then susceptible to cytotoxic
attack by embryonic antigen sensitized
lymph node cells. Immunization of syn-
geneic rats with tumour cells also elicits
lymph node cells sensitized towards the
tumour associated embryonic antigens
since these LNC are cytotoxic in vitro
for embryo cells (Baldwin et al., 1974).
As demonstrated in the present study, this
cytotoxicity can be blocked by pretreating
embryo cells with multiparous rat serum,
thus offeringfurtherevidence thatimmuni-
zation with tumour cells elicits an immune
response to embryonic antigens.
It has previously been argued (Baldwin
et al., 1971b; 1972a, b) on grounds of
antigen specificities that the individually
distinct tumour rejection antigens on
rat hepatomata and sarcomata differ
from the cross-reacting tumour associated
embryonic antigens. This postulate is
further supported by the data reported
in this paper since pretreatment of
plated tumour cells with multiparous rat
serum did not block them from the
cytotoxic attack of specifically sensitized
LNC from tumour immune rats. Since
these LNC preparations contain cells
cytotoxic for embryo cells and this reac-
tion can be blocked by multiparous
serum, it is concluded that tumour
immunization produced different LNC
populations sensitized to embryonic and
tumour specific antigens. The cytotoxi-
city mediated by LNC reacting with
embryonic antigens expressed on either
embryo or tumour cells will be blocked
by multiparous serum. The cytotoxicity
mediated by LNC reacting with the
individually distinct tumour antigens will
then be restricted to tumour cells and, as
evidenced by the present study, will not
be blocked by multiparous serum. The
reactivity, however, can be specifically
blocked by serum from tumour immune
rats (Baldwin et al., 1973b). In this case,
tumour immune serum blocks only cells
of the immunizing tumour from cytotoxic
attack by tumour immune LNC, again
indicating that individual tumour antigens
are being detected.
Further differentiation between the
individual tumour specific and embryonic
antigens on rat hepatomataand sarcomata
is provided by the experiments on their
subeellular localization. The tumour spe-
cific antigens expressed on rathepatomata
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(Baldwin and Moore, 1969; Baldwin,
Harris and Price, 1973d) and sarcomata
(Baldwin andPimm, unpublishedfindings)
are intimately associated with the plasma
membrane. Following cell rupture, tu-
mour specific antigen, defined by its
capacity to absorb antibody from syn-
geneic tumour immune serum, is isolated
only in cell membrane fractions. The
soluble cytoplasmic fraction does not
contain detectable antigen. This is fur-
therevidenced by the failure ofimmuniza-
tion of syngeneic rats with cytoplasmic
fractions to elicit tumour specific anti-
body, although membrane fractions retain
immunogenicity (Baldwin and Moore,
1969; Baldwin, Embleton and Moore,
1973a). Also, release of tumour specific
antigen from isolated membrane fractions
can be effected only by disruptive pro-
cedures such as papain solubilization
(Baldwin and Glaves, 1972; Baldwin et
al., 1973d).
The methods used to demonstrate
embryonic antigens on tumour cells
(lymph node cell cytotoxicity, membrane
immunofluorescence staining of bound
immunoglobulin and complement depen-
dent serum cytotoxicity) establish that
these antigens are expressed at the cell
surface membrane (Baldwin et al., 1971b;
1972b). However, following rupture of
either tumour or embryo cells, embryonic
antigen is detectable in the cytoplasmic
fraction. This is demonstrated by the
capacity of cell sap fractions to neutralize
antibody in multiparous rat serum react-
ing with cell membrane expressed antigens
on tumour cells. Also, immunization of
syngeneic rats with tumour and 14-day
old embryo cell saps elicits antibody to
embryonic antigens so that sera from
these rats consistently gave positive
immunofluorescence staining with embryo
cells. Significantly, as already indicated,
there is no concomitant production of
tumour specific antibody. These findings
suggest that the tumour associated embry-
onic antigens may be primarily intra-
cellular proteins showing transient expres-
sion at the cell surface or, alternatively,
they may be weakly associated plasma
membrane products readily detaching on
cell rupture.
If the embryonic antigen is primarily
an intracellular product, two possibilities
could account for its appearance at the
cell surface. It may be continuously
synthesized in the cytoplasm and leak
out or be secreted on to the cell surface.
Alternatively, the antigen detected at the
plasma membrane may be synthesized
there from a large pool of preformed
determinants in the cytoplasm. The
former seems more likely upon com-
parison with the properties of other cell
surface expressed antigens. Thus, as
already discussed, the tumour rejection
antigen is detectable only at the plasma
membrane and no antigen activity codld
be shown in the cell cytoplasm. Sinii-
larly, recent work on HL-A histocom-
patibility antigens suggests that HL-A2
is synthesized de novo at the plasma
membrane and that a large pool of
preformed determinants is not present
in the cells (Turner, Strominger and
Sanderson, 1972). Earlier studies on
mouse H-2 antigens also indicated that
disrupted cells had only slightly more
alloantibody absorbing capacity than an
equivalent number of intact cells (Haugh-
ton, 1966). Confirmation that a pre-
cursor: product relationship between the
cytoplasmic and cell surface expressed
embryonic antigens must, however, await
precise biochemical characterization of
these components.
The finding of two separate neo-
antigen expressions at the cell surface
of rat hepatomata and sarcomata is in
agreement with studies by Ting et al.,
(1972) on SV40 and polyoma induced
mouse tumours. By differential absorp-
tion of antibody from syngeneic antisera
to foetal or tumour cells, it was established
that the tumour rejection antigens and
embryonic antigens were different. Also,
in the studies of Thomson and Alexander
(1973) and Menard, Calnaghi and Della
Porta (1973) two antigenic specificities
were detected on polycyclic hydrocarbon
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induced sarcomata. One of these, the
tumour specific transplantation antigen,
was characterized by its individual tumour
specificity, whilst the second was shared
between different tumours and present
on embryo cells. This separation of the
embryonic and tumour specific antigens
may not apply in all situations, however,
and Coggin et al. (1970, 1971) suggest
that in SV40 virus induced tumours in
the hamster, the two antigens may be
identical since immunization with irradi-
ated foetal tissue led to the induction
of tumour immunity. In this system
the status ofthe identity between the two
antigens is not settled since females did
not respond to foetal immunization as
well as males, although no such disparity
is evident upon immunization to tumour.
Subsequent studies (Coggin and Anderson,
1972) have not resolved this disparity.
The present studies demonstrate that
the tumour specific antigens, viewed as
being of primary importance in tumour
rejection, are different from the embryonic
antigens common to cells of 14- to 16-day
old embryos and tumours. It cannot be
excluded, however, that the tumour
specific antigens are other embryonic
antigens rather than being the products
of new genetic information introduced
by carcinogen induced changes (Baldwin,
1973). During foetal development there
may be a multiplicity of genes coding for
polypeptides, some of which may be
expressed only for short times, or on a
limited number of cells. Such antigenic
specificities would not be detectable by
the methods employed in this study so
that the origin of the diverse tumour
specific antigens on chemically induced
tumours is still not resolved.
This work was supported by a grant
from the Cancer Research Campaign and
by the award to one of us (B. M. V.)
of a Medical Research Council Student-
ship for Training in Research.
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